Transcriptomics-Based Characterization of the Toxicity of ZnO Nanoparticles Against Chronic Myeloid Leukemia Cells

References

• Handy RD, Von der Kammer F, Lead JR, Hassellöv M, Owen R, Crane M. The ecotoxicology and chemistry of manufactured nanoparticles. Ecotoxicology. 2008;17(4):287–314. doi:10.1007/s10646-008-0199-818351458
   PubMed Web of Science ®Google Scholar
• Govindaraju K, Krishnamoorthy K, Alsagaby SA, Singaravelu G, Premanathan M. Green synthesis of silver nanoparticles for selective toxicity towards cancer cells. IET Nanobiotechnol. 2015;9:325–330. doi:10.1049/iet-nbt.2015.000126647807
   PubMed Web of Science ®Google Scholar
• Ke Y, Al Aboody MS, Alturaiki W, et al. Photosynthesized gold nanoparticles from Catharanthus roseus induces caspase-mediated apoptosis in cervical cancer cells (HeLa). Artif Cells Nanomed Biotechnol. 2019;47:1938–1946. doi:10.1080/21691401.2019.161401731099261
   PubMed Web of Science ®Google Scholar
• Kawata K, Osawa M, Okabe S. In vitro toxicity of silver nanoparticles at noncytotoxic doses to HepG2 human hepatoma cells. Environ Sci Technol. 2009;43:6046–6051. doi:10.1021/es900754q19731716
   PubMed Web of Science ®Google Scholar
• Rajeshkumar S. Anticancer activity of eco-friendly gold nanoparticles against lung and liver cancer cells. J Genetic Eng Biotechnol. 2016;14:195–202. doi:10.1016/j.jgeb.2016.05.007
   PubMedGoogle Scholar
• Foldbjerg R, Dang DA, Autrup H. Cytotoxicity and genotoxicity of silver nanoparticles in the human lung cancer cell line, A549. Arch Toxicol. 2011;85:743–750. doi:10.1007/s00204-010-0545-520428844
   PubMed Web of Science ®Google Scholar
• Gurunathan S, Han JW, Eppakayala V, Jeyaraj M, Kim J-H. Cytotoxicity of biologically synthesized silver nanoparticles in MDA-MB-231 human breast cancer cells. Biomed Res Int. 2013;2013.
   Web of Science ®Google Scholar
• Jiang J, Pi J, Cai J. The advancing of zinc oxide nanoparticles for biomedical applications. Bioinorg Chem Appl. 2018;2018.
   Web of Science ®Google Scholar
• Premanathan M, Karthikeyan K, Jeyasubramanian K, Manivannan G. Selective toxicity of ZnO nanoparticles toward Gram-positive bacteria and cancer cells by apoptosis through lipid peroxidation. Nanomed Nanotechnol Biol Med. 2011;7:184–192. doi:10.1016/j.nano.2010.10.001
   PubMed Web of Science ®Google Scholar
• Boroumand Moghaddam A, Moniri M, Azizi S, et al. Eco-friendly formulated zinc oxide nanoparticles: induction of cell cycle arrest and apoptosis in the MCF-7 cancer cell line. Genes. 2017;8:281.
   PubMed Web of Science ®Google Scholar
• Cao Y, Roursgaard M, Kermanizadeh A, Loft S, Møller P. Synergistic effects of zinc oxide nanoparticles and fatty acids on toxicity to caco-2 cells. Int J Toxicol. 2015;34(1):67–76. doi:10.1177/109158181456003225421740
   PubMed Web of Science ®Google Scholar
• Akhtar MJ, Ahamed M, Kumar S, Khan MAM, Ahmad J, Alrokayan SA. Zinc oxide nanoparticles selectively induce apoptosis in human cancer cells through reactive oxygen species. Int J Nanomedicine. 2012;7:845.22393286
   PubMed Web of Science ®Google Scholar
• Bai D-P, Zhang X-F, Zhang G-L, Huang Y-F, Gurunathan S. Zinc oxide nanoparticles induce apoptosis and autophagy in human ovarian cancer cells. Int J Nanomedicine. 2017;12:6521. doi:10.2147/IJN.S14007128919752
   PubMed Web of Science ®Google Scholar
• Pandurangan M, Enkhtaivan G, Kim DH. Anticancer studies of synthesized ZnO nanoparticles against human cervical carcinoma cells. J Photochem Photobiol B Biol. 2016;158:206–211. doi:10.1016/j.jphotobiol.2016.03.002
   PubMed Web of Science ®Google Scholar
• Bisht G, Rayamajhi S. ZnO nanoparticles: a promising anticancer agent. Nanobiomedicine. 2016;3:3–9. doi:10.5772/6343729942378
   PubMedGoogle Scholar
• Shen C, James SA, de Jonge MD, Turney TW, Wright PFA, Feltis BN. Relating cytotoxicity, zinc ions, and reactive oxygen in ZnO nanoparticle–exposed human immune cells. Toxicol Sci. 2013;136:120–130.23997113
   PubMed Web of Science ®Google Scholar
• Manke A, Wang L, Rojanasakul Y. Mechanisms of nanoparticle-induced oxidative stress and toxicity. Biomed Res Int. 2013;2013.
   Web of Science ®Google Scholar
• Lowe R, Shirley N, Bleackley M, Dolan S, Shafee T. Transcriptomics technologies. PLoS Comput Biol. 2017;13.
   Web of Science ®Google Scholar
• Hanagata N, Xu M, Takemura T, Zhuang F. Cellular response to ZnO nanoparticle toxicity inferred from global gene expression profiles. Nano Biomedicine. 2010;2:153–169.
   Google Scholar
• Moos PJ, Olszewski K, Honeggar M, et al. Responses of human cells to ZnO nanoparticles: a gene transcription study. Metallomics. 2011;3:1199–1211.21769377
   PubMed Web of Science ®Google Scholar
• Poon W-L, Alenius H, Ndika J, et al. Nano-sized zinc oxide and silver, but not titanium dioxide, induce innate and adaptive immunity and antiviral response in differentiated THP-1 cells. Nanotoxicology. 2017;11:936–951. doi:10.1080/17435390.2017.138260028958187
   PubMed Web of Science ®Google Scholar
• Tuomela S, Autio R, Buerki-Thurnherr T, et al. Gene expression profiling of immune-competent human cells exposed to engineered zinc oxide or titanium dioxide nanoparticles. PLoS One. 2013;8.
   Web of Science ®Google Scholar
• Lozzio CB, Lozzio BB. Human Chronic Myelogenous Leukemia Cell-Line with Positive Philadelphia Chromosome. 1975.
   Google Scholar
• Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring. Am J Hematol. 2018;93:442–459.29411417
   PubMed Web of Science ®Google Scholar
• An X, Tiwari AK, Sun Y, Ding P-R, Ashby CR Jr, Chen Z-S. BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review. Leuk Res. 2010;34(10):1255–1268. doi:10.1016/j.leukres.2010.04.01620537386
   PubMed Web of Science ®Google Scholar
• Druker BJ, Guilhot F, O’Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408–2417.17151364
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Larson RA, Guilhot F, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017;376(10):917–927. doi:10.1056/NEJMoa160932428273028
   PubMed Web of Science ®Google Scholar
• Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65(1–2):55–63. doi:10.1016/0022-1759(83)90303-46606682
   PubMed Web of Science ®Google Scholar
• Reimand J, Arak T, Adler P, et al. g: profiler—a web server for functional interpretation of gene lists (2016 update). Nucleic Acids Res. 2016;44:W83–W89. doi:10.1093/nar/gkw19927098042
   PubMed Web of Science ®Google Scholar
• Triboulet S, Aude-Garcia C, Armand L, et al. Analysis of cellular responses of macrophages to zinc ions and zinc oxide nanoparticles: a combined targeted and proteomic approach. Nanoscale. 2014;6:6102–611424788578
   PubMed Web of Science ®Google Scholar
• Mishra PK, Mishra H, Ekielski A, Talegaonkar S, Vaidya B. Zinc oxide nanoparticles: a promising nanomaterial for biomedical applications. Drug Discov Today. 2017;22(12):1825–1834. doi:10.1016/j.drudis.2017.08.00628847758
   PubMed Web of Science ®Google Scholar
• Si M, Lang J. The roles of metallothioneins in carcinogenesis. J Hematol Oncol. 2018;11:107.30139373
   PubMed Web of Science ®Google Scholar
• Dua P, Chaudhari KN, Lee C-H, et al. Evaluation of toxicity and gene expression changes triggered by oxide nanoparticles. Bull Korean Chem Soc. 2011;32(6):2051–2057. doi:10.5012/bkcs.2011.32.6.2051
   Web of Science ®Google Scholar
• Lee SH, Pie J-E, Kim Y-R, Lee HR, Son SW, Kim M-K. Effects of zinc oxide nanoparticles on gene expression profile in human keratinocytes. Mol Cell Toxicol. 2012;8(2):113–118. doi:10.1007/s13273-012-0014-8
   Web of Science ®Google Scholar
• Zheng Y, Jiang L, Hu Y, et al. Metallothionein 1H (MT1H) functions as a tumor suppressor in hepatocellular carcinoma through regulating Wnt/β-catenin signaling pathway. BMC Cancer. 2017;17:161. doi:10.1186/s12885-017-3139-228241806
   PubMed Web of Science ®Google Scholar
• Liu Z. Ye, Q., Wu, L., et al. Metallothionein 1 family profiling identifies MT1X as a tumor suppressor involved in the progression and metastastatic capacity of hepatocellular carcinoma. Mol Carcinog. 2018;57:1435–1444. doi:10.1002/mc.2284629873415
   PubMed Web of Science ®Google Scholar
• Wang Y, Wang, G, Tan, X, et al. MT1G serves as a tumor suppressor in hepatocellular carcinoma by interacting with p53. Oncogenesis. 2019;8:1–11. doi:10.1038/s41389-019-0176-530631034
   PubMed Web of Science ®Google Scholar
• Mao J, Yu H, Wang C, et al. Metallothionein MT1M is a tumor suppressor of human hepatocellular carcinomas. Carcinogenesis. 2012;33:2568–2577. doi:10.1093/carcin/bgs28722971577
   PubMed Web of Science ®Google Scholar
• Han YC, Zheng ZL, Zuo ZH, et al. Metallothionein 1 h tumour suppressor activity in prostate cancer is mediated by euchromatin methyltransferase 1. J Pathol. 2013;230:184–193.23355073
   PubMed Web of Science ®Google Scholar
• Demidenko R, Daniunaite K., Bakavicius A., et al. Decreased expression of MT1E is a potential biomarker of prostate cancer progression. Oncotarget. 2017;8:61709. doi:10.18632/oncotarget.1868328977898
   PubMedGoogle Scholar
• Fu J, Lv H, Guan H, et al. Metallothionein 1G functions as a tumor suppressor in thyroid cancer through modulating the PI3K/Akt signaling pathway. BMC Cancer. 2013;13:462. doi:10.1186/1471-2407-13-46224098937
   PubMed Web of Science ®Google Scholar
• Chen Y, Quan R,Bhandari A, et al. Low metallothionein 1M (MT1M) is associated with thyroid cancer cell lines progression. Am J Transl Res. 2019;11:1760.30972199
   PubMed Web of Science ®Google Scholar
• Appierto V. Villani MG, Cavadini, E, et al. Involvement of c-Fos in fenretinide-induced apoptosis in human ovarian carcinoma cells. Cell Death Differ. 2004;11:270–279. doi:10.1038/sj.cdd.440134914647238
   PubMed Web of Science ®Google Scholar
• Takekawa M, Saito H. A family of stress-inducible GADD45-like proteins mediate activation of the stress-responsive MTK1/MEKK4 MAPKKK. Cell. 1998;95:521–530. doi:10.1016/S0092-8674(00)81619-09827804
   PubMed Web of Science ®Google Scholar
• Yoo J, Ghiassi, M, Jirmanova L., et al. Transforming grow th factor-β-induced apoptosis is mediated by Smad-dependent expression of GADD45b through p38 activation. J Biol Chem. 2003;278:43001–43007. doi:10.1074/jbc.M30786920012933797
   PubMed Web of Science ®Google Scholar
• Boone DN, Qi Y, Li Z, Hann SR. Egr1 mediates p53-independent c-Myc–induced apoptosis via a noncanonical ARF-dependent transcriptional mechanism. Proc Natl Acad Sci. 2011;108:632–637. doi:10.1073/pnas.100884810821187408
   PubMed Web of Science ®Google Scholar
• Yu J, Baron V, Mercola D, Mustelin T, Adamson ED. A network of p73, p53 and Egr1 is required for efficient apoptosis in tumor cells. Cell Death Differ. 2007;14(3):436. doi:10.1038/sj.cdd.440202916990849
   PubMed Web of Science ®Google Scholar
• Kim J-H, Yoon S, Won M, et al. HIP1R interacts with a member of Bcl-2 family, BCL2L10, and induces BAK-dependent cell death. Cell Physiol Biochem. 2009;23(1–3):043–52. doi:10.1159/000204088
   PubMedGoogle Scholar
• Yun CW, Kim HJ, Lim JH, Lee SH. Heat shock proteins: agents of cancer development and therapeutic targets in anti-cancer therapy. Cells. 2020;9:60.
   Web of Science ®Google Scholar
• Chowanadisai W, Kelleher SL, Lonnerdal BO. Zinc deficiency is associated with increased brain zinc import and LIV-1 expression and decreased ZnT-1 expression in neonatal rats. J Nutr. 2005;135:1002–1007. doi:10.1093/jn/135.5.100215867272
   PubMed Web of Science ®Google Scholar
• Aude-Garcia C, Dalzon B, Ravanat J-L, et al. A combined proteomic and targeted analysis unravels new toxic mechanisms for zinc oxide nanoparticles in macrophages. J Proteomics. 2016;134:174–185. doi:10.1016/j.jprot.2015.12.01326710724
   PubMed Web of Science ®Google Scholar
• García-Hevia L, Valiente R, Martín-Rodríguez R, et al. Nano-ZnO leads to tubulin macrotube assembly and actin bundling, triggering cytoskeletal catastrophe and cell necrosis. Nanoscale. 2016;8:10963–10973. doi:10.1039/C6NR00391E27228212
   PubMed Web of Science ®Google Scholar
• Edling CE, Hallberg B. c-Kit—a hematopoietic cell essential receptor tyrosine kinase. Int J Biochem Cell Biol. 2007;39(11):1995–1998. doi:10.1016/j.biocel.2006.12.00517350321
   PubMed Web of Science ®Google Scholar
• Rönnstrand L. Signal transduction via the stem cell factor receptor/c-Kit. Cell Mol Life Sci. 2004;61:2535–2548. doi:10.1007/s00018-004-4189-615526160
   PubMed Web of Science ®Google Scholar
• Schleussner N, Merkel O, Costanza M., et al. The AP-1-BATF and-BATF3 module is essential for growth, survival and TH17/ILC3 skewing of anaplastic large cell lymphoma. Leukemia. 2018;32:1994–2007. doi:10.1038/s41375-018-0045-929588546
   PubMed Web of Science ®Google Scholar
• Logan MR, Jordan-Williams KL, Poston S, Liao J, Taparowsky EJ. Overexpression of Batf induces an apoptotic defect and an associated lymphoproliferative disorder in mice. Cell Death Dis. 2012;3:e310–e10. doi:10.1038/cddis.2012.4922592317
   PubMed Web of Science ®Google Scholar
• Shivtiel S, Lapid K, Kalchenko V, et al. CD45 regulates homing and engraftment of immature normal and leukemic human cells in transplanted immunodeficient mice. Exp Hematol. 2011;39(1161–70):e1.
   Google Scholar
• Ma Y. Han, C.-C.; Huang, Q.; Sun, W.-Y. and Wei, W. GRK2 overexpression inhibits IGF1-induced proliferation and migration of human hepatocellular carcinoma cells by downregulating EGR1. Oncol Rep. 2016;35:3068–3074. doi:10.3892/or.2016.464126936374
   PubMed Web of Science ®Google Scholar
• Tagoug I, De Chalon AS, Dumontet C. Inhibition of IGF-1 signalling enhances the apoptotic effect of AS602868, an IKK2 inhibitor, in multiple myeloma cell lines. PLoS One. 2011;6.
   Web of Science ®Google Scholar
• Strömberg T, Ekman S, Girnita L, et al. IGF-1 receptor tyrosine kinase inhibition by the cyclolignan PPP induces G2/M-phase accumulation and apoptosis in multiple myeloma cells. Blood. 2006;107:669–678. doi:10.1182/blood-2005-01-030616166596
   PubMed Web of Science ®Google Scholar
• Park H, Chan, MM and Iritani, BM. Hem-1: putting the “WAVE” into actin polymerization during an immune response. FEBS Lett. 2010;584:4923–4932.20969869
   PubMed Web of Science ®Google Scholar
• Joshi AD, Hegde GV, Dickinson JD, et al. ATM, CTLA4, MNDA, and HEM1 in High versus Low CD38–Expressing B-cell chronic lymphocytic leukemia. Clin Cancer Res. 2007;13:5295–5304. doi:10.1158/1078-0432.CCR-07-028317875758
   PubMed Web of Science ®Google Scholar
• Cao L, Branstrom A, Baird J, et al. PTC299 is a novel DHODH inhibitor that modulates VEGFA mRNA translation and inhibits proliferation of a broad range of leukemia cells. Blood. 2017;130:1371.
   Web of Science ®Google Scholar
• Ghosh A, Dasgupta D, Ghosh A, et al. MiRNA199a-3p suppresses tumor growth, migration, invasion and angiogenesis in hepatocellular carcinoma by targeting VEGFA, VEGFR1, VEGFR2, HGF and MMP2. Cell Death Dis. 2017;8(3):e2706–e06. doi:10.1038/cddis.2017.12328358369
   PubMed Web of Science ®Google Scholar
• Moser B, Wolf M, Walz A,et al. Chemokines: multiple levels of leukocyte migration control. Trends Immunol 2004;25:75–84.
   Google Scholar
• Mukaida N. Tanabe, Y. and Baba, T. Chemokines as a conductor of bone marrow microenvironment in chronic myeloid leukemia. Int J Mol Sci. 2017;18:1824. doi:10.3390/ijms18081824
   PubMed Web of Science ®Google Scholar
• Olsnes AM, Hatfield KJ, Bruserud Ø. The chemokine system and its contribution to leukemogenesis and treatment responsiveness in patients with acute myeloid leukemia. J BUON. 2009;14:S131–40.19785055
   PubMed Web of Science ®Google Scholar
• Burger J A. Chemokines and chemokine receptors in chronic lymphocytic leukemia (CLL): from understanding the basics towards therapeutic targeting. Seminars in cancer biology 2010;20:424–430.
   Google Scholar
• Vainchenker W, Constantinescu SN. JAK/STAT signaling in hematological malignancies. Oncogene. 2013;32:2601–2613.22869151
   PubMed Web of Science ®Google Scholar
• Steelman LS, Pohnert SC, Shelton JG, Franklin RA, Bertrand FE, McCubrey JA. JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia. 2004;18:189–218.14737178
   PubMed Web of Science ®Google Scholar
• Faderl S, Ferrajoli A, Harris D, et al. Atiprimod blocks phosphorylation of JAK-STAT and inhibits proliferation of acute myeloid leukemia (AML) cells. Leuk Res. 2007;31:91–95. doi:10.1016/j.leukres.2006.05.02716828865
   PubMed Web of Science ®Google Scholar
• Hayakawa F, Sugimoto K, Harada Y, et al. A novel STAT inhibitor, OPB-31121, has a significant antitumor effect on leukemia with STAT-addictive oncokinases. Blood Cancer J. 2013;3:e166–e66. doi:10.1038/bcj.2013.6324292418
   PubMed Web of Science ®Google Scholar
• Zhao S, Konopleva M, Cabreira-Hansen M, et al. Inhibition of phosphatidylinositol 3-kinase dephosphorylates BAD and promotes apoptosis in myeloid leukemias. Leukemia 2004;18:267–275.
   Google Scholar
• Barragán M, Bellosillo B, Campas C, et al. Involvement of protein kinase C and phosphatidylinositol 3–kinase pathways in the survival of B-cell chronic lymphocytic leukemia cells. Blood J Am Soc Hematol. 2002;99:2969–2976.
   Google Scholar
• Herman SEM, Gordon AL, Wagner AJ, et al. Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood J Am Soc Hematol. 2010;116:2078–2088.
   Google Scholar
• Ashrafizadeh M, Ahmadi Z, Kotla NG, et al. Nanoparticles targeting STATs in cancer therapy. Cells. 2019;8:1158. doi:10.3390/cells8101158
   PubMed Web of Science ®Google Scholar
• Matarrese P, Fusco O, Tinari N, et al. Galectin‐3 overexpression protects from apoptosis by improving cell adhesion properties. Int J Cancer. 2000;85:545–554. doi:10.1002/(SICI)1097-0215(20000215)85:4<545::AID-IJC17>3.0.CO;2-N10699929
   PubMed Web of Science ®Google Scholar
• Okada K. Hirota E, Mizutani Y, et al. Oncogenic role of NALP7 in testicular seminomas. Cancer Sci. 2004;95:949–954. doi:10.1111/j.1349-7006.2004.tb03182.x15596043
   PubMed Web of Science ®Google Scholar
• Zeng C, Li X, Li A, et al. Knockdown of NUPR1 inhibits the growth of U266 and RPMI8226 multiple myeloma cell lines via activating PTEN and caspase activation‑dependent apoptosis. Oncol Rep. 2018;40:1487–1494.30015974
   PubMed Web of Science ®Google Scholar
• An S, Zheng, Y. and Bleu, T. Sphingosine 1-phosphate-induced cell proliferation, survival, and related signaling events mediated by G protein-coupled receptors Edg3 and Edg5. J Biol Chem. 2000;275:288–296. doi:10.1074/jbc.275.1.28810617617
   PubMed Web of Science ®Google Scholar
• Nogueira DR, Rolim CMB, Farooqi AA. Nanoparticle induced oxidative stress in cancer cells: adding new pieces to an incomplete jigsaw puzzle. Asian Pac J Cancer Prev. 2014;15:4739–4743. doi:10.7314/APJCP.2014.15.12.473924998535
   PubMedGoogle Scholar
• Zelko IN, Mariani TJ, Folz RJ. Superoxide dismutase multigene family: a comparison of the CuZn-SOD (SOD1), Mn-SOD (SOD2), and EC-SOD (SOD3) gene structures, evolution, and expression. Free Radic Biol Med. 2002;33:337–349. doi:10.1016/S0891-5849(02)00905-X12126755
   PubMed Web of Science ®Google Scholar
• Gelain DP, Dalmolin RJS, Belau VL, Moreira JCF, Klamt F, Castro MA. A systematic review of human antioxidant genes. Front Biosci. 2009;14:4457–4463. doi:10.2741/3541
   Web of Science ®Google Scholar
• Muthuraman P, Ramkumar K, Kim DH. Analysis of dose-dependent effect of zinc oxide nanoparticles on the oxidative stress and antioxidant enzyme activity in adipocytes. Appl Biochem Biotechnol. 2014;174:2851–2863. doi:10.1007/s12010-014-1231-525234395
   PubMed Web of Science ®Google Scholar
• Syama S, Reshma SC, Sreekanth PJ, Varma HK, Mohanan P. V. Effect of zinc oxide nanoparticles on cellular oxidative stress and antioxidant defense mechanisms in mouse liver. Toxicol Environ Chem. 2013;95:495–503. doi:10.1080/02772248.2013.789606
   Web of Science ®Google Scholar
• MacMillan-Crow LA, Thompson JA. Tyrosine modifications and inactivation of active site manganese superoxide dismutase mutant (Y34F) by peroxynitrite. Arch Biochem Biophys. 1999;366:82–88. doi:10.1006/abbi.1999.120210334867
   PubMed Web of Science ®Google Scholar
• Folz RJ, Crapo JD. Extracellular superoxide dismutase (SOD3): tissue-specific expression, genomic characterization, and computer-assisted sequence analysis of the human EC SOD gene. Genomics. 1994;22:162–171. doi:10.1006/geno.1994.13577959763
   PubMed Web of Science ®Google Scholar
• Jaramillo-Gutierrez G, Molina-Cruz A, Kumar S, Barillas-Mury C. The Anopheles gambiae oxidation resistance 1 (OXR1) gene regulates expression of enzymes that detoxify reactive oxygen species. PLoS One. 2010;5.
   Google Scholar
• Wang X, Wang L, Wang XE, Sun F, WangC-C. Structural insights into the peroxidase activity and inactivation of human peroxiredoxin 4. Biochem J. 2012;441:113–118. doi:10.1042/BJ2011038021916849
   PubMed Web of Science ®Google Scholar
• Arthur JR. The glutathione peroxidases. Cell Mol Life Sci. 2001;57:1825–1835. doi:10.1007/PL00000664
   Web of Science ®Google Scholar
• Hanschmann E-M, Godoy JR, Berndt C, Hudemann C, Lillig CH. Thioredoxins, glutaredoxins, and peroxiredoxins—molecular mechanisms and health significance: from cofactors to antioxidants to redox signaling. Antioxid Redox Signal. 2013;19:1539–1605. doi:10.1089/ars.2012.459923397885
   PubMed Web of Science ®Google Scholar
• Liu H, Lu Z-G, Miki Y, Yoshida K. Protein kinase C δ induces transcription of the TP53 tumor suppressor gene by controlling death-promoting factor Btf in the apoptotic response to DNA damage. Mol Cell Biol. 2007;27:8480–8491. doi:10.1128/MCB.01126-0717938203
   PubMed Web of Science ®Google Scholar
• Lee JH, Kang Y, Khare V, et al. The p53-inducible gene 3 (PIG3) contributes to early cellular response to DNA damage. Oncogene. 2010;29:1431–1450. doi:10.1038/onc.2009.43820023697
   PubMed Web of Science ®Google Scholar
• Lugovskoy AA, Zhou P, Chou JJ, McCarty JS, Li P, Wagner G. Solution structure of the CIDE-N domain of CIDE-B and a model for CIDE-N/CIDE-N interactions in the DNA fragmentation pathway of apoptosis. Cell. 1999;99:747–755. doi:10.1016/S0092-8674(00)81672-410619428
   PubMed Web of Science ®Google Scholar
• Liang L, Zhao, M, Xu Z, Yokoyama KK, Li T. Molecular cloning and characterization of CIDE-3, a novel member of the cell-death-inducing DNA-fragmentation-factor (DFF45)-like effector family. Biochem J. 2003;370:195–203. doi:10.1042/bj2002065612429024
   PubMed Web of Science ®Google Scholar
• Iglesias-Guimarais V, Gil-Guiñon E, Gabernet G, et al. Apoptotic DNA degradation into oligonucleosomal fragments, but not apoptotic nuclear morphology, relies on a cytosolic pool of DFF40/CAD endonuclease. J Biol Chem. 2012;287:7766–7779. doi:10.1074/jbc.M111.29071822253444
   PubMed Web of Science ®Google Scholar
• Huang DCS, Strasser A. BH3-only proteins—essential initiators of apoptotic cell death. Cell. 2000;103:839–842. doi:10.1016/S0092-8674(00)00187-211136969
   PubMed Web of Science ®Google Scholar
• Xue L, Chu F, Cheng Y, et al. Siva-1 binds to and inhibits BCL-XL-mediated protection against UV radiation-induced apoptosis. Proc Natl Acad Sci. 2002;99:6925–6930. doi:10.1073/pnas.10218229912011449
   PubMed Web of Science ®Google Scholar
• Vogler M. BCL2A1: the underdog in the BCL2 family. Cell Death Differ. 2012;19:67–74. doi:10.1038/cdd.2011.15822075983
   PubMed Web of Science ®Google Scholar
• He M-X, He Y-W. c-FLIP protects T lymphocytes from apoptosis in the intrinsic pathway. J Immunol. 2015;194:3444–3451. doi:10.4049/jimmunol.140046925725104
   PubMed Web of Science ®Google Scholar
• Deveraux QL, Reed JC. IAP family proteins—suppressors of apoptosis. Genes Dev. 1999;13:239–252. doi:10.1101/gad.13.3.2399990849
   PubMed Web of Science ®Google Scholar
• Chau BN, Cheng EHY, Kerr DA, Hardwick JM. Aven, a novel inhibitor of caspase activation, binds Bcl-xL and Apaf-1. Mol Cell. 2000;6:31–40. doi:10.1016/S1097-2765(05)00021-310949025
   PubMed Web of Science ®Google Scholar
• Chen L, Willis, SN, Wei A, et al. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell. 2005;17:393–403. doi:10.1016/j.molcel.2004.12.03015694340
   PubMed Web of Science ®Google Scholar
• Borrelli A, Schiattarella A, Mancini R, et al. A recombinant MnSOD is radioprotective for normal cells and radiosensitizing for tumor cells. Free Radic Biol Med. 2009;46:110–116. doi:10.1016/j.freeradbiomed.2008.10.03018996183
   PubMed Web of Science ®Google Scholar
• Chen P-M, Cheng Y-W, Wu T-C, Chen C-Y, Lee H. MnSOD overexpression confers cisplatin resistance in lung adenocarcinoma via the NF-κB/Snail/Bcl-2 pathway. Free Radic Biol Med. 2015;79:127–137. doi:10.1016/j.freeradbiomed.2014.12.00125499851
   PubMed Web of Science ®Google Scholar
• Nagata S. Fas ligand-induced apoptosis. Annu Rev Genet. 1999;33:29–55. doi:10.1146/annurev.genet.33.1.2910690403
   PubMed Web of Science ®Google Scholar
• Hsu H, Huang J, Shu H-B, Baichwal V, Goeddel DV. TNF-dependent recruitment of the protein kinase RIP to the TNF receptor-1 signaling complex. Immunity. 1996;4:387–396. doi:10.1016/S1074-7613(00)80252-68612133
   PubMed Web of Science ®Google Scholar
• Walczak H, Degli‐Esposti MA, Johnson RS, et al. TRAIL‐R2: a novel apoptosis‐mediating receptor for TRAIL. EMBO J. 1997;16:5386–5397. doi:10.1093/emboj/16.17.53869311998
   PubMed Web of Science ®Google Scholar
• Salvesen GS. Caspase 8: igniting the death machine. Structure. 1999;7:R225–R29. doi:10.1016/S0969-2126(00)80048-910545333
   PubMed Web of Science ®Google Scholar
• Gilmore TD. Introduction to NF-κB: players, pathways, perspectives. Oncogene. 2006;25(51):6680–6684. doi:10.1038/sj.onc.120995417072321
   PubMed Web of Science ®Google Scholar
• Reber L, Vermeulen L, Haegeman G, Frossard N. Ser276 phosphorylation of NF-kB p65 by MSK1 controls SCF expression in inflammation. PLoS One. 2009;4:e4393. doi:10.1371/journal.pone.000439319197368
   PubMed Web of Science ®Google Scholar
• Bandapalli OR, Ehrmann F, Ehemann V, et al. Down-regulation of CXCL1 inhibits tumor growth in colorectal liver metastasis. Cytokine. 2012;57:46–53. doi:10.1016/j.cyto.2011.10.01922129625
   PubMed Web of Science ®Google Scholar
• Liu J-Y, Zeng Q-H, Cao P-G, et al. RIPK4 promotes bladder urothelial carcinoma cell aggressiveness by upregulating VEGF-A through the NF-κB pathway. Br J Cancer. 2018;118:1617–1627.29867225
   PubMed Web of Science ®Google Scholar
• Hamidi T, Algül H, Cano CE, et al. Nuclear protein 1 promotes pancreatic cancer development and protects cells from stress by inhibiting apoptosis. J Clin Invest. 2012;122:2092–2103. doi:10.1172/JCI6014422565310
   PubMed Web of Science ®Google Scholar
• You Z, Ouyang H, Lopatin D, Polver PJ, WangC-Y. Nuclear factor-κB-inducible death effector domain-containing protein suppresses tumor necrosis factor-mediated apoptosis by inhibiting caspase-8 activity. J Biol Chem. 2001;276:26398–26404. doi:10.1074/jbc.M10246420011346652
   PubMed Web of Science ®Google Scholar
• Gyrd-Hansen M, Meier P. IAPs: from caspase inhibitors to modulators of NF-κB, inflammation and cancer. Nat Rev Cancer. 2010;10:561–574.20651737
   PubMed Web of Science ®Google Scholar
• Matsuda A, Suzuki Y, Honda G, et al. Large-scale identification and characterization of human genes that activate NF-κ B and Mapk signaling pathways. Oncogene. 2003;22:3307–3318. doi:10.1038/sj.onc.120640612761501
   PubMed Web of Science ®Google Scholar